Analysts See $-0.17 EPS for Aptose Biosciences Inc. (APTO)

July 14, 2018 - By James Douglas

Analysts expect Aptose Biosciences Inc. (NASDAQ:APTO) to report $-0.17 EPS on August, 14.They anticipate $0.06 EPS change or 54.55 % from last quarter’s $-0.11 EPS. After having $-0.23 EPS previously, Aptose Biosciences Inc.’s analysts see -26.09 % EPS growth. The stock decreased 4.18% or $0.14 during the last trading session, reaching $3.21. About 513,609 shares traded or 14.83% up from the average. Aptose Biosciences Inc. (NASDAQ:APTO) has risen 252.94% since July 14, 2017 and is uptrending. It has outperformed by 240.37% the S&P500.

Aptose Biosciences Inc. (NASDAQ:APTO) Ratings Coverage

Among 2 analysts covering Aptose Biosciences (NASDAQ:APTO), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aptose Biosciences had 6 analyst reports since March 28, 2018 according to SRatingsIntel. The rating was maintained by Roth Capital with “Buy” on Tuesday, June 5. Roth Capital maintained it with “Buy” rating and $600 target in Monday, April 16 report. H.C. Wainwright maintained Aptose Biosciences Inc. (NASDAQ:APTO) rating on Wednesday, March 28. H.C. Wainwright has “Buy” rating and $600 target. The stock of Aptose Biosciences Inc. (NASDAQ:APTO) earned “Buy” rating by H.C. Wainwright on Monday, April 16. The firm earned “Buy” rating on Monday, May 7 by H.C. Wainwright. The firm has “Buy” rating given on Friday, June 15 by H.C. Wainwright.

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. The company has market cap of $109.15 million. The Company’s lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. It currently has negative earnings. The firm has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma.

More notable recent Aptose Biosciences Inc. (NASDAQ:APTO) news were published by: Benzinga.com which released: “Benzinga’s Daily Biotech Pulse: Biohaven Sells Right To Drug, Obseva To Sell Shares” on June 19, 2018, also Globenewswire.com with their article: “FDA Lifts Clinical Hold so MYC Inhibitor APTO-253 Can Return to Phase 1b Trial In Patients With Hematologic Cancers” published on June 29, 2018, Nasdaq.com published: “Aptose Presents New CG-806 Data at the 23rd Congress of the European Hematology Association” on June 15, 2018. More interesting news about Aptose Biosciences Inc. (NASDAQ:APTO) were released by: Nasdaq.com and their article: “Aptose Biosciences to Participate at the Oppenheimer & Co. Inc. Boston Oncology Insight Summit and 1×1 Day” published on July 09, 2018 as well as Benzinga.com‘s news article titled: “28 Stocks Moving In Thursday’s Pre-Market Session” with publication date: July 05, 2018.

Aptose Biosciences Inc. (NASDAQ:APTO) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: